Table 1.
Patient and tumour characteristics
| Velocity of diameter expansion <4 mm/year n = 11 (55%) | Velocity of diameter expansion ≥4 mm/year n = 9 (45%) | p | |
| Age (years) | 42.4 ± 11.4 | 41.1 ± 10.3 | 0.80 |
| Female gender | 4 (36%) | 6 (67%) | 0.37 |
| Time between MRI 1 and PET (days) | 41.0 ± 23.2 | 40.8 ± 18.9 | 0.98 |
| Time between PET and histology (days) | 106.1 ± 77.6 | 90.7 ± 55.5 | 0.61 |
| Time between MRI 1 and MRI 2 (days) | 81.9 ± 24.5 | 82.4 ± 36.3 | 0.97 |
| WHO 2016 Classification | |||
| Diffuse astrocytoma, IDH-mutant | 6 (55%) | 2 (22%) | 0.20 |
| Anaplastic astrocytoma, IDH-mutant | 3 (27%) | 2 (22%) | 1 |
| Diffuse astrocytoma, IDH-wildtype | 0 | 2 (22%) | 0.19 |
| Anaplastic astrocytoma, IDH-wildtype | 0 | 1 (11%) | 0.45 |
| Oligodendroglioma, IDH-mutant and 1p 19q codeleted | 2 (18%) | 1 (11%) | 1 |
| Anaplastic oligodendroglioma, IDH-mutant and 1p 19q codeleted | 0 | 1 (11%) | 0.45 |
| IDH mutation | 11 (100%) | 6 (66%) | 0.07 |
| Anaplastic | 3 (27%) | 4 (36%) | 0.64 |
| SUVmax T/N | 1.6 ± 0.9 | 1.0 ± 0.3 | 0.06 |
| SUVmax T/N > 1.8 | 5 (45%) | 0 (0%) | 0.04 |
IDH mutation,isocitrate deshydrogenase mutation; PET, positron emission tomography; SUV, standardized uptake value; T/N, tumour/contralateral normal brain tissue uptake; WHO, World Health Organization.